TABLE 1.

Current drugs for leishmaniasis (parenteral administration unless otherwise stated)

Type of leishmaniasisStatus of drugsDrugs
VisceralFirst-line drugsSodium stibogluconate (Pentostam); meglumine antimoniate (Glucantime)
Amphotericin B (Fungizone)
Liposomal amphotericin B (AmBisome)
Pentamidine
Clinical trialsMiltefosine (oral, phase IV)
Paromomycin (phase III)
Sitamaqine (oral, phase II)
Other amphotericin B formulations
CutaneousFirst-line drugsSodium stibogluconate (Pentostam); meglumine antimoniate (Glucantime)
Amphotericin B (Fungizone)
Pentamidine
Paromomycin (topical formulations with methylbenzethonium chloride or urea)
Clinical trialsMiltefosine (oral, phase III; registered in Colombia in 2005)
Paromomycin (topical formulation with gentamicin and surfactants, phase II)
Imiquimod (topical immunomodulator, phase II)
Antifungal azoles (ketoconazole, fluconazole, itraconazole)